6月23日 - ** 药物开发商Leap Therapeutics LPTX.O股价盘前上涨30.9%至46美分
** 该公司表示, (link),将裁员 75%,以减少开支和保护资本。
** LPTX还在探索其实验性候选药物sirexatamab和FL-501的潜在销售或合作机会
** LPTX表示,其实验性药物sirexatamab在一项中期试验中显示,所有接受过一次治疗的二线结直肠癌患者的治疗反应和无进展生存期均有所改善。
** 截至2025年3月31日,公司的现金及现金等价物总额为3270万美元。
** 截至上次收盘,LPTX 的股价在过去一年中下跌了 86.9
(为便利非英文母语者,路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误,或未能包含所需语境,路透不保证自动化翻译文本的准确性,仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失,路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.